Award Number: DAMD17-98-1-8633

TITLE: Insecticide Exposure in Parkinsonism

PRINCIPAL INVESTIGATOR: Jeffrey R. Bloomquist, Ph.D.

CONTRACTING ORGANIZATION: Virginia Polytechnic Institute and State University Blacksburg, Virginia 24061

REPORT DATE: January 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 3

AD

1

20000424 213

				טטוט-איזט. טאין בוא
Dublic reporting burden for this collection of inform he data needed, and completing and reviewing the reducing this burden to Washington Headquarters	nation is estimated to average 1 hour per resp is collection of information. Send comments is Services, Directorate for Information Operation Services, Directorate for Information Operation	onse, including the time for reviewing in egarding this burden estimate or any o ons and Reports, 1215 Jefferson Davis	nstructions, searching exi- other aspect of this collect Highway, Suite 1204, Art	sting data sources, gathering and maintaining ion of information, including suggestions for ington, VA 22202-4302, and to the Office of
Management and Budget, Paperwork Reduction F 1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE January 2000	3. REPORT TYPE ANI Annual (1 Jan	D DATES COVERE 99 - 31 Dec	D 99)
. TITLE AND SUBTITLE Insecticide Exposure i:	n Parkinsonism	L	5. FUNDING N DAMD17-98-	JMBERS -1-8633
			-	
. AUTHOR(S) Jeffrey R. Bloomqu	ist, Ph.D.			
PERFORMING ORGANIZATION I	NAME(S) AND ADDRESS(ES) 1 State University		8. PERFORMIN REPORT NU	G ORGANIZATION MBER
31acksburg, Virginia 24061				
E-MAIL: bquist@vt.edu 9. SPONSORING / MONITORING A	GENCY NAME(S) AND ADDRES	S(ES)	10. SPONSORI	
U.S. Army Medical Research and Fort Detrick, Maryland 21702-5	d Materiel Command 012	• .	AGENUTR	EFORT NUMBER
11. SUPPLEMENTARY NOTES			L	
12a. DISTRIBUTION / AVAILABILIT Approved for public re	YSTATEMENT lease; distribution	unlimited	<u></u>	12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Wo A series of behavioral characterize the possi disease as it may rela organophosphorus compo- two week period by in Permethrin showed an u at least two orders of mg/kg), the increase i effects may have been found that transporter caused small, but stat activity. However, cy were not changed by 10 an increase in dopamin increase in titers of Chlorpyrifos at 25-100 correlated reasonably behaviors. Permethrin been related to a doul with >50 mg/kg. These	rds; , neurochemical, and ble role of insectic ate to Gulf War Syndr ound chlorpyrifos and pection (chlorpyrifos up-regulation of dopa magnitude below its in transport declined involved, since immu staining was near c cistically significan ytotoxicity was not r 00 mg/kg chlorpyrifos he turnover at 100 mg the dopamine metabol 0 mg/kg caused 15-84% well with effects on h caused a significan bling of muscarinic r e studies demonstrate	immunocytochemica ide exposure in th ome. The insection the pyrethroid, p subcutaneous and mine transport at LD50. At higher to a level below nocytochemical lak ontrol levels. Bo t decreases in mit eflected in levels or 200 mg/kg pern /kg chlorpyrifos, ite, 3,4-dihydroxy inhibition of acc open field, rear: t decline in open eceptor density in	al studies w he etiology cides under permethrin g permethrin a dose of 1 doses of pe that of com beling of th oth permethr tochondrial s of striata methrin. Th as indicate yphenylaceti etylcholines ing, and pol field behav n the striat cts on dopar	ere undertaken to of Parkinson's study are the iven 3 times over a intraperitoneal). .5 mg/kg, which is ermethrin (>25 trol. Toxic te caudate-putamen in and chlorpyrifos dehydrogenase al dopamine, which here was, however, ed by a significant c acid. sterase, which e climbing vior, which may have tum of mice treated mine neurochemistry
14. SUBJECT TERMS		<u></u>		15. NUMBER OF PAGES 39

Parkinson's disease, p permethrin, MPTP, pyre	arkinsonism, neurotoxic throid, synergism	ity, chlorpyrifos,	16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited
NSN 7540-01-280-5500			Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. 239-18

Prescribed by ANS 298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

May 17 Bhompust 2/1/00 - Signature Date

TABLE OF CONTENTS

(1)	Front Cover1
(2)	Standard Form 2982
(3)	Foreword
(4)	Table of Contents4
(5)	Introduction
(6)	Body5
(7)	Key Research Accomplishments
(8)	Reportable Outcomes
(9)	Conclusions
(10)	References 14
(11)	Appendices16

INTRODUCTION

This project is focused on Parkinson's disease (PD) as a long term consequence of Gulf War Syndrome, with insecticides evaluated as causative agents. The experiments for the first year are related to Objective #1, which is to characterize any effects on biomarkers of PD over a range of doses of permethrin (PM) and chlorpyrifos (CPF). Treatments were given in three injections over a two week period, exactly as described in the proposal (Fig. 1). The plan of work emphasizes studies on permethrin, with chlorpyrifos experiments following later in the year. Results of doseresponse studies, along with the observed effects on PD biomarkers, are listed below in the Body of the Report, in the order outlined in the amended proposal.

BODY

Overall, we have performed the majority, but not all, of the experiments planned for the first year. Two major factors limited our ability to complete all of the scheduled experiments. First, we lost 5 months of postdoctoral effort due to the timing of employment. Although the project started on 1/1/99, Dr. Wen Li was unable to join the group until 3/1/99. In addition, Dr. Paul Harp resigned from this study 9/30/99 in order to take a position in the State Toxicologist's Office in New Hampshire. We have just hired an excellent young scientist, Dr. Daniel Karen, into the vacant postdoctoral position, and he started work on 1/25/00. A copy of his resume is included in the Appendices. The other problem concerned a two month construction/maintenance procedure on our Laboratory Animal facility that resulted in loss of temperature control in the animal holding rooms. This problem led to heat stress in the animals and unreliable data, which was excluded from the report. This maintenance problem, which has been rectified, is described in a detailed letter from Dr. David Moore, University Veterinarian (see the last item in the Appendices).

a. Assess toxicant effects on dopamine titers and turnover by measuring the dopamine and 3,4-dihydroxyphenyl acetic acid (DOPAC) content of the striata from treated mice.

Methods: HPLC analysis was performed exactly as described in the proposal. High doses of PM and CPF were tested in these initial studies, since we felt that loss of dopamine would be an indicator of relatively more intense effects on the striatum, compared to other biomarkers.

Results and Discussion: Our first experiments with CPF at 150 mg/kg resulted in lethality in 4 of 7 mice (57%), so the top dose was reduced to 100 mg/kg, where only 4 mice died out of the 42 treated (9.5% mortality). At 50 mg/kg CPF there was 7% mortality (2 out of 28 mice), one of which was a bad ip injection. Thus, mortality below 100 mg/kg is probably unrelated to toxicant action. No mortality was observed in any of the mice treated with PM.

Once the maximal doses were established, we began the striatal dopamine analysis. Dopamine content was about 160 pmoles/mg striatum in controls (Fig. 2). High doses of CPF (100 mg/kg) and PM (200 mg/kg) had no effect on dopamine content of the striatum, compared to controls treated with appropriate solvents. There was, however, a significant elevation of DOPAC by CPF treatment, about 14% above control levels (Fig. 3). In contrast, PM treatment had no effect on DOPAC titers, which averaged about 8 pmoles/mg striatum wet weight, in controls (Fig. 3).

Loss of dopamine and DOPAC is a cardinal sign of PD (Hornykiewicz and Kish, 1987) and can reflect changes in both neuronal electrical activity and cell death in the striatum. Elevated levels of DOPAC indicate greater turnover of dopamine in response to toxicant-induced processes (Hudson *et al.*, 1985). We assume that CPF increases turnover through its well-known ability to cause neuronal hyperexcitation through inhibition of acetylcholinesterase. We were somewhat surprised by the lack of any effect of PM, given that increased striatal DOPAC occurs following treatment with the pyrethroids deltamethrin (Kirby *et al.*, 1999) and fenvalerate (Husain *et al.*, 1991).

However, fenvalerate and deltamethrin have much greater mammalian acute toxicity toxic than PM, with rat oral $LD_{50}s$ of 31, 451, and 3801 mg/kg for deltamethrin, fenvalerate, and PM, respectively (Budavari *et al.*, 1996).

We have previously speculated that enhanced turnover of dopamine may itself be neurotoxic, because the metabolism and auto-oxidation of dopamine generates cellular oxidative stress (Dawson *et al.*, 1995) and high levels of dopamine in the brain can be neurotoxic (Filloux and Townsend, 1993). However, we would expect that cell toxicity would be reflected in a loss of striatal dopamine, but this effect was not observed, perhaps due to the short duration of exposure (two weeks). Overall, we do not think the lack of dopamine depletion by these insecticides when given alone is very surprising. If insecticides were frank parkinsonian agents, like the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), this activity would have been documented by now, given the large number of toxicity studies that have been performed over the years on pyrethroids and especially, chlorpyrifos. Subtle, predisposing effects of these compounds, or synergistic interactions, are more likely to be involved in environmental parkinsonism.

b. Assess effects on the density and kinetic properties of dopamine transporters in striatal synaptosomes from treated mice.

Methods: Exactly as described in the proposal for dopamine uptake. We have also established methods for $[^{3}H]GBR12935$ binding, but have not yet run this assay on treated mice.

Results and Discussion: We observed that PM treatment significantly alters maximal transport (V_{max}) of dopamine with little effect on half maximal substrate affinity (K_m) . Figure 4 shows representative results for V_{max} and K_m determinations in our initial experiments having three treatment groups, two of which were treated with 100 or 200 mg/kg PM. Kinetic data given beneath Figure 4 confirms that the major effect of PM was a significant depression of V_{max} , with no effect on K_m (all K_m values have extensive overlap in their 95% confidence limits). These experiments were replicated over a broad range of doses (two experiments at each dose), and the results are summarized in the bar graph in Figure 5. The lowest doses of PM (0.2, 0.4, and 0.8 mg/kg) had little or no effect on dopamine uptake. So, these doses presumably represent the threshold for this biomarker, although we expect to see some evidence of enhanced uptake at 0.8 mg/kg in additional replicates. A peak increase in maximal transport of dopamine was observed at 1.5 mg/kg, and this effect lapsed into a depression of uptake at much higher doses (Fig. 5).

These studies were initiated at high doses (100 and 200 mg/kg PM), with the dose reduced in twofold steps (Fig. 5). Thus, they represent a significant amount of effort, and we kept reducing the dose because we had observed an upregulation in dopamine transport in mice treated with deltamethrin (Kirby *et al.*, 1999). The dose of PM where upregulation occurs (1.5 mg/kg) is miniscule compared to its LD_{50} , and 200 mg/kg ip caused no lethality, no overt signs of toxicity, and no effect in our behavioral studies (see below). Thus, 1.5 mg/kg is at least 2 orders of magnitude less than a nonlethal dose. It is also important to note that technical permethrin is a mixture of four stereoisomers (Fig. 6), only one of which (1*R*, 3*R*, *cis*) is expected to have any toxic effects in mammals, based on studies of acute lethality (Casida *et al.*, 1983). If so, the true level of toxic isomer in these studies is 0.375 mg/kg. A few more replicates of these studies around the 1.5 mg/kg point are required, so the ultimate shape of this response curve and the maximal increase in transport at 1.5 mg/kg PM remain to be finalized.

The level of increased dopamine transport caused by PM (mean of two experiments: 50% above control) is about the same as that observed for cocaine, which raises expression 50% when given 5 times/day at 40 mg/kg (Miller *et al.*, 1993). In contrast to PD, schizophrenia results from dopamine overactivity (Bowman and Rand, 1980) and dopamine uptake in postmortem brain preparations from schizophrenic patients was increased 74% over controls (Haberland and Hetey, 1987). Thus, the level of DAT overexpression in schizophrenia appears similar to that resulting from low dose

exposures to PM. Moreover, psychiatric problems are known to result from OP exposure and disturbance of consciousness has been reported for pyrethroid intoxication in man (He *et al.*, 1988).

We speculate that the dopamine transporter was up-regulated in response to increased levels of synaptic dopamine, which is consistent with findings we recently published on the structurallyrelated pyrethroid, deltamethrin (Kirby et al., 1999). We expect to confirm upregulation of DAT by immunocytochemical labeling (biomarker f) in animals treated with 1.5 mg/kg PM. We also expect We have recently that levels of [³H]GBR12935 binding will go up by a similar amount. documented that the organochlorine insecticide heptachlor virtually doubles dopamine transport, and that antibody labeling of DAT in western blots of synaptosomal protein is increased by a similar amount (Miller et al., 1999). Moreover, the dose-response curve for heptachlor has a shape similar to that reported here for PM. Cytotoxicity is the simplest explanation for the depression of uptake at higher doses. We would expect toxicity to be reflected in loss of striatal dopamine, which was not observed (Fig. 2). However, there is evidence of cell stress in mice treated with PM, as measured in the MTT assay (see next section). At higher doses, toxicity in nerve terminals could mask up-regulated transporter density in synaptosomal uptake experiments; if, for example, toxic processes result in greater leakage of dopamine from presynaptic stores, in vitro. Thus, at higher doses, there may not be a clear correlation between uptake, GBR binding, and immunocytochemical labeling, which we do expect to see at doses near 1.5 mg/kg PM. Our studies with heptachlor (Miller et al., 1999) were not run at a range of doses wide enough to shed much light on this possibility.

Pilot studies of GBR binding in albino mice are shown in Figure 7, demonstrating our ability to perform this assay. For these studies, striatal synaptosomes are harvested, and then subjected to repeated resuspension in distilled water, followed by centrifugation, following the procedure Marks *et al.* (1986) developed for measuring [³H]nicotine binding. The tissue is then stored frozen until ready for use. Equilibrium binding parameters for [³H]GBR12935 are given with the binding curve in Figure 7, which also shows the dose-dependence and saturation of [³H]GBR12935 binding. Autoradiographic methods of measuring [³H]GBR12935 binding in brain slices found a similar K_d of 1.4 nM, but not surprisingly, a lower binding capacity (B_{max}) of 6 pmol/mg protein (Richfield, 1991), compared to our studies in well-washed synaptosomal membranes. We place a high priority on performing the GBR binding assay in mice treated with the doses of PM shown in Figure 5, for comparison with the uptake data.

Overall, these findings suggest that transporter activity/expression is a sensitive biomarker for toxicity in neurotransmitter systems where the transporter is the primary mechanism for terminating transmitter action. It is interesting to note that for cholinergic synapses, where acetylcholinesterase terminates transmitter action, chlorpyrifos slightly decreases (16-20%) choline uptake (Liu *et al.*, 1995), indicating a different regulatory mechanism. Increased transporter expression or activity would augment neuronal accumulation of endogenous or exogenous pyridinium toxins (*e.g.*, MPP⁺, the oxidation product of MPTP), thereby providing a likely mechanism of synergism in our planned studies with MPTP.

c. Compare the extent of toxin-dependent actions on mitochondrial function in striatal synaptosomes by measuring thiazolyl blue dehydrogenase activity.

Methods: The thiazolyl blue (MTT) assay kit from Sigma Chemical Co. (St. Louis, Missouri), which reports on the amount of dehydrogenase activity at mitochondrial complex 1 (Slater *et al.*, 1963) was used essentially as described in the proposal. We use synaptosomes instead of brain mitochondria in order to assess respiration of mitochondria in a cellular environment approximating what they experience *in vivo*, which we hypothesize will be altered by poisoning. Accordingly respiration of isolated mitochondria in artificial media may not be an accurate reflection of their *in vivo* activity.

Results and Discussion: Preliminary experiments using the MTT assay in synaptosomes from treated mice found that it does not follow typical kinetics (Fig. 8). The reduction of MTT is linear with respect to concentration, up to about 0.5 mM, where the activity saturates and then declines at higher substrate concentrations. Comparison of curves from controls and mice treated with CPF at 13 mg/kg and controls showed significant overlap, up to 0.55 mM MTT. The 25 mg/kg CPF group actually had slightly higher levels of activity compared to controls up to saturation. Above 0.55 mM, the responses changed, with the 13 mg/kg group less than controls and the 25 mg/kg The concentration-response relationship at higher MTT group declining to control levels. concentrations is not predictive or consistent with relative activity at lower substrate levels. Given this somewhat unusual dependence on substrate concentration, in subsequent experiments we emphasized effects at concentrations up to 0.55 mM, which is at or near maximal effect. Statistically significant reductions of dehydrogenase activity, the anticipated effect of insecticides, occurring at two MTT concentrations should provide additional confidence that any observed effect is biologically significant. At the highest tested dose of CPF (100 mg/kg), there was a consistent reduction (about 20%) in MTT dehydrogenase activity (Fig. 9). There was no consistent effect of CPF at doses ≤0 mg/kg, but a slight increase, probably simply related to assay variability, was observed at 0.55 mM MTT. Additional replicates will clarify whether the reduction in mitochondrial function observed at 100 mg/kg is manifested across different groups of mice.

Consistent effects on MTT dehydrogenase activity were also observed after PM treatment. The results of these studies are shown in the two bar graphs of Figure 10. In the lower dose group (13, 25, and 50 mg/kg) activity was depressed at both 0.38 and 0.55 mM MTT, with a dose-response relationship especially evident at the latter substrate concentration. Reduction of mitochondrial activity at these doses is consistent with the reduced transport documented in the previous section. Surprisingly, at higher doses only 200 mg/kg PM showed a statistically significant inhibition of dehydrogenase activity (10% at 0.55 mM MTT). The reason for the lack of effect at 100 mg/kg remains unclear. Additional replicates of these studies are planned.

Toxicity to nerve terminals *in vivo* should be reflected in reduced mitochondrial function *in vitro*. We have observed small, but statistically significant reductions in mitochondrial activity, which is also observed in PD (Schapira *et al.*, 1990) and other neurodegenerative diseases (Beal *et al.*, 1993).

- d. Search for anatomical evidence of general neurotoxicity within light microscopic preparations of the nigro-striatal system by examining glial fibrillary acidic protein (GFAP) immunoreactivity as a marker for gliosis.
- e. Search for anatomical evidence of neurotoxicity within specific dopaminergic neurochemical components of the nigro-striatal system using immunohistochemical staining for the catecholamine-synthesizing enzymes tyrosine hydroxylase (TH) and dopamine beta hydroxylase (DBH).
- f. Confirm whether functional changes in dopamine transport are due to fluctuating levels of the dopamine transporter (DAT) protein using immunohistochemical identification.

Methods: These biomarkers are dealt with together because fixation, sectioning, staining, and analysis is similar for all these studies. Much time during the first reporting period was devoted to the hiring and training of a graduate student (Graduate Research Assistant) to cut brain tissue and perform the immunohistochemical procedures. This required some fine-tuning of our proposed protocols, primarily in terms of reagent and antibody concentrations, for use in the nigro-striatal system. In addition, the SigmaScan Pro image analysis software, which we originally proposed to use for quantitative analysis, proved difficult to work with for our intended purpose. Therefore, a

considerable period of time was devoted to development of our own novel image analysis protocol using Adobe Photoshop 5.0 and the training of personnel to use it. A description of this protocol is provided below.

First, the control and treated slices are mounted on the same slide and stained under identical conditions. Then, positions of the fields to be measured are specified for each coronal section through the striatum. This is done with the aid of a camera lucida attachment to a microscope. The external border of the caudate-putamen (CPu) is identified and traced using the external capsule as an anatomical marker. Along the arc of this external border, a mark is then made at 1/3 and 2/3 of the distance between its ventral-most point and the dorsal ventricular border of the nucleus. The central point of the CPu is then quantified and a radius is drawn from the 1/3 and 2/3 markers to the center of the cPu. Along each of these two radii, a mark is made 1/4 and 1/2 the distance from the lateral border of the nucleus to the center point of the nucleus. This yields four locations within the CPu from which measurements of immunolabel will be made. Since the CPu comprises the dorsal portion of the striatum, which is the primary locus of nigral dopaminergic afference to the striatum. An example of the position of the four fields to be measured is indicated on appended Figure 11.

After specifying the four loci to be measured in each section, a digital image was captured from the nearest homogenous terminal field to each locus, using the 100X objective. The digital images from each section were then analyzed using the histogram function of Adobe Photoshop. After converting the image to grayscale, the histogram function can provide mean or median grayscale value (0-256, with 0 being black and 256 white), pixel count for a single specified gray value or total pixel count for a continuous range of grayscale values.

In general, a mean minimum acceptable grayscale value was determined for immunolabeled neuropil for each control brain. This value was also applied to a matched treated brain. A given measurement looked at the total number of pixels that were darker (smaller in grayscale value) than the mean minimum acceptable grayscale value (e.g. if mean minimum value was 102, looked at total number of pixels from grayscale values of 102 to 0).

To determine mean minimum acceptable grayscale value, first the mean value of two immunolabeled varicosities per field, judged as the minimum acceptable for measurement, was determined. Then the grand section mean across the four fields per section was determined. Finally, a grand mean for the brain was determined from each of the grand section means. Again, this minimum acceptable value of the grayscale, measured from a given control brain, was used to make pixel counts on that brain and its corresponding pesticide-matched brain. This determines the change relative to the control brain.

Pixel counts were then made as follows: For each of the four fields for a given section, the grayscale histogram was examined for the entire image. Then, the number of pixels with a value less than (darker than) the minimum acceptable grayscale value was determined. For example, if mean minimum value was 102, looked at total number of pixels from grayscale values of 102 to 0. The count for each field was used to produce a section mean of pixel counts. The mean for each section was then used to calculate a brain mean pixel count. The procedure was then repeated for the matched treated brain, and the percent change in mean pixel counts was calculated between the two brains. This percent change is one data point to be used in a matched pairs comparison of means.

Results and Discussion: We have begun processing striatal tissue for anatomical biomarkers of PD to determine the effects of each of the pesticides alone, and compared them to MPTP as a positive control. We have processed two vehicle controls and two brains each from mice treated with MPTP (30 mg/kg), a low dose of PM (1.5 mg/kg), a high dose of PM (200 mg/kg), and 100 mg/kg CPF. Only the MPTP-treated brains exhibit obvious differences between vehicle control

upon visual inspection. Examples of this change for DAT immunoreactive neuropil are illustrated in the appended Figure 12. The control image (Fig. 12A) shows intense and evenly distributed staining for DAT. After treatment with MPTP, overall staining is reduced and is less evenly distributed, as more staining is evident along the left margin of the Cpu (Fig. 12B). At higher magnification (Fig. 12 C,D), the staining appears uniform over small areas. Quantitative analysis of DAT staining following MPTP treatment detected a mean 77.1% decrease in DAT immunolabel relative to vehicle controls (Fig. 13). This is an important finding for our project since it shows that our digital analysis protocol is capable of detecting a well defined change in dopaminergic afference to the striatum that has been demonstrated in other labs (Heikkila and Sonsalla, 1992). The high dose permethrin treatment produced a minimal 7% increase in DAT immunolabel (Fig. 13). Our current sample size precludes meaningful statistical analysis of these results, but this data does suggest that there are near normal levels of DAT in the striatum of mice treated with 200 mg/kg PM. Thus, other cytotoxic factors probably underlie the reduced dopamine uptake consistently observed at this dose.

We are intrigued by the apparent non-uniform distribution of DAT in the immunocytochemical studies of MPTP, and wonder if a related phenomenon might be occurring in PM- or CPF-treated mice with respect to dopamine levels. Recall that we observed no change in dopamine content of the striatum following PM or CPF treatment (Fig. 2). However, what if some terminals are depleted of dopamine, and other increase production to compensate. A hypothetical example of this idea is shown in Figure 14. Would a uniform immunostaining for dopamine become non-uniform, reduced in some areas, but more intense in others? Immunostaining coronal sections for dopamine would address this issue.

An example of TH immunoreactive profiles from a chlorpyrifos-treated mouse is also appended (Fig. 15), simply to illustrate the staining. The quantitative analysis of this data is not finished, and more mice will be processed shortly. If a pesticide treatment causes a reduction in specific dopaminergic inputs to the striatum (TH staining is reduced), we will process brains for immunocytochemical analysis of dopaminergic cells in the substantia nigra, as well. For pesticide treatments that fail to produce any change in specific dopaminergic afference to the striatum, we will examine GFAP immunoreactivity for evidence of a more generalized neurotoxic response. Although we originally stated that we would also process brains for dopamine beta hydroxylase immunoreactivity to distinguish noradrenergic from dopaminergic striatal neuropil, it has since come to our attention that there is an insignificant noradrenergic innervation of the striatum (Aston-Jones *et al.*, 1995). We conclude that these studies are moot.

In terms of methodological improvements, we continue to fine tune our procedure in an attempt to reduce the concentration of antibody necessary for visualizable staining. This would reduce the cost of tissue processing. We are also attempting to maximize the number of brains that can be processed at one time. We have just hired an individual to fill the wage position, which will increase our tissue processing output. We expect to rapidly accelerate our processing of tissue in the second year of the project.

g. Explore toxicant effects on open field/rearing frequencies and pole climbing behaviors and search for correlations between behavioral impairment and neurochemical effects.

Methods: Behavioral experiments focused on measurements of impairment of motor function and were performed essentially as described in the proposal.

Results and Discussion: CPF had dose-dependent effects on movement, rearing, and pole climbing behavior. Open field movement (Fig. 16) was unaffected by 25 mg/kg CPF, but inhibited about by 36% at 50 mg/kg and 71% by 100 mg/kg. Similarly, rearing (Fig. 16) was not changed by 25 mg/kg CPF, but 50 mg/kg reduced rearing frequency 29% and at 100 mg/kg rearing was

reduced by 76%. Only the responses at 100 mg/kg CPF were statistically significant. In the pole traction test (Fig. 17), CPF caused a dose-dependent increase in the percentage of mice that fell from the pole that confounded our planned measurements of descent time. We will replicate this analysis in order to do conventional statistical analysis. We prefer this approach as opposed to nonparametric statistical analysis of this type of data.

Permethrin treatment had only limited effects on behavioral performance. There was a slight trend for a decrease in movement as the dose was increased from 0.2 to 200 mg/kg (Fig. 18). There was a statistically significant inhibitory effect at a dose of 50 mg/kg. The small magnitude of the effect and inherent variability of behavioral data probably contributed to the lack of significance at other doses. No effect was observed in the rearing measurements (Fig. 18) or in the descent time measurement of the pole test (Fig. 19). Descent time proved to be the most variable of all the behavioral measures. In three cases, we excluded data from individual mice that hung from the pole for more than 180 sec and never attempted to climb down (control, 13, 25, and 50 mg/kg groups, all from the same cohort of mice). A score of 180 sec for down time is more than three standard deviations from the mean. Unlike CPF, no falls were recorded after treatment of PM at any dose.

PD results in tremors, bradykinesia, and incoordination (Bowman and Rand, 1980), which are reflected in the behavioral assays we have performed.. These behavioral studies have allowed us to observe some general correlations between behavior and neurochemical effects. Thus, we expect to observe tremors and bradykinesia that should correlate with depletion of dopamine or other neurochemical effects in future studies.

h. Determine the extent of acetylcholinesterase inhibition following treatment with toxicants for comparison with other behavioral and neurochemical effects.

Methods: We used the classical method of Ellman *et al.* (1961) to determine acetylcholinesterase activity in striatal synaptosomes from treated mice. The assay measures enzyme generation of yellow color by reaction of 5,5'-dithiobis-2-nitrobenzoic acid and thiocholine when acetylcholine is used as the enzyme substrate. Although V_{max} and K_m values for acetylcholinesterase activity were planned, standard measurement of cholinesterase involves a single substrate concentration at an incubation time in the linear range of activity. We used a substrate concentration of 400 mM and an incubation time of 3 min.

Results and Discussion: CPF at 25, 50, and 100 mg/kg gave 15%, 58%, and 85% inhibition of acetylcholinesterase (Fig. 20). Thus, the dynamic range of inhibition is essentially covered by these doses. The maximal level of cholinesterase inhibition observed at 100 mg/kg CPF is similar to that reported for rat striatum (82-96% inhibition) treated with CPF or parathion (Liu and Pope, 1998). The extent of acetylcholinesterase inhibition by CPF typically does not correlate with effects on behavior (Nostrandt *et al.*, 1997), possibly due to compensatory changes in muscarinic receptors (Nostrandt *et al.*, 1997) and high affinity choline uptake (Liu *et al.*, 1995). In the present study, however, there was a reasonable match between enzyme inhibition and behavioral effects (movement, rearing, and falling; Figs. 16 and 17). Moreover, there was about 15% mortality at 50 mg/kg and about 20% mortality at 200 mg/kg, although the mice showed no signs of SLUD.

We also observed an effect of PM treatment on acetylcholinesterase activity. In this case, there was an increase in enzyme activity in treated mice (Fig. 21). The effect was small, typically an increase of 10-20%, and was not clearly dose-dependent, so the biological relevance is somewhat questionable. It is interesting to note that exposure to deltamethrin also caused a small but significant increase in acetylcholinesterase activity in rat brain (Husain *et al.* 1994). Perhaps this effect is an adaptive response to high levels of synaptic acetylcholine caused by the pyrethroids.

i. Define any toxicant-induced changes in cholinergic receptor density or function with respect to agonist-induced dopamine release from striatal synaptosomes.

Methods: This goal of the research actually contains several separate neurochemical measurements. We have established methods for radioligand binding studies involving [³H]quinuclidinyl benzilate ([³H]QNB) and [³H]nicotine, with nicotine binding adapted from the procedures of Marks *et al.* (1986). In addition, two methods for measuring functional cholinergic modulation of dopamine release are still under development. The first will measure loss of label by repeated application of buffer with a pipettor. Alternatively, the labeled synaptosomes will have agonists superfused over them with a peristaltic pump and loss of label will be quantified in this manner. We have not yet performed any studies on the ability of cholinergic agonists to alter release of dopamine in striatal synaptosomes from insecticide-treated mice.

Results and Discussion:

In mouse brain striatal synaptosomes from controls, we observed [³H]QNB binding characteristics of K_d values in the picomolar range (13 pM) and11 pmol/mg protein for B_{max} (Fig. 22). This compares reasonably well with the values reported for heart membranes by Goodwin *et al.* (1995) of $K_d = 60$ pM and $B_{max} = 401$ fmol/mg protein. In addition, there is a good match between our Bmax value and that reported by Nostrandt *et al.* (1997), which was about 2.8 pmol/mg protein in rat striatum.

Exposing mice to PM causes an apparent upregulation of muscarinic receptors, as evidenced by an increase in the B_{max} for [³H]QNB binding (Fig. 22). Compared to controls, QNB binding was increased 86% at 50 mg/kg, 131% at 100 mg/kg, and 111% at 200 mg/kg PM (Table with Fig. 22). There were also changes in K_d , but there was considerable overlap in the 95% confidence limits for these values (Table with Fig. 22). We have not performed any studies of striatal QNB binding in mice treated with CPF. However, the known effect of chlorpyrifos to down-regulate muscarinic receptors in the striatum (Chaudhuri et al., 1993) makes it likely that we will confirm this effect of CPF, which is opposite that of PM. This difference is interesting, since both pesticides are expected to increase synaptic levels of acetylcholine, but differ in how this action affects receptor regulation. Systemic injection of pyrethroids (ca. 1 mg/kg) in young mice slightly down-regulated cortical expression of muscarinic receptors (5-10%), but apparently not in the striatum (Eriksson and Fredriksson, 1991). These results however, may be suspect, since Eriksson and Fredriksson (1991) report a K_d value in the low micromolar range of what they call high affinity QNB binding. This data is several orders of magnitude different from the K_d we report (13 pM), as well as that found by others: Goodwin *et al.* (1995) for heart ($K_d = 63$ pM) and Niemeyer *et al.* (1995) for cat retina ($K_d = 270 \text{ pM}$). We feel it is imperative to replicate our PM results to ensure our complete confidence in the observation of up-regulated muscarinic receptors.

It is interesting to note what is known of the role of muscarinic receptors in the control of motor behavior as it relates to our results with PM and its up-regulation of muscarinic receptors. Muscarinic agonists mimic the bradykinesia and tremor seen in PD (Gomeza *et al.*, 1999), and we observed a slight decrease in open field movement following PM treatment (Fig. 18). Perhaps the doubling in muscarinic receptor density caused by PM is in part responsible.

Although we have not yet measured effects in treated mice, we have a reasonable assay in place to perform experiments on [³H]nicotine binding (Fig. 23). In these studies, nicotine shows saturable binding with specific binding about %80 of total binding at 5 nM ligand. Our K_d value of 2.1 nM is similar to the 8 nM reported by Marks *et al.* (1986). We have a number of processed tissues from treated mice that are stored frozen at -70 °C and ready to be used in binding studies (Table 1). Thus, we will be able to make rapid progress on all the binding studies in the near future.

KEY RESEARCH ACCOMPLISHMENTS

- Demonstration of dopamine transport up-regulation at extremely low doses of technical permethrin (1.5 mg/kg).
- Found small, but statistically significant reductions in mitochondrial activity occurred in PM- and CPF-treated mice.

Observed a large up-regulation of striatal muscarinic receptors by PM treatment.

Inhibition of acetylcholinesterase by CPF was correlated with open field, rearing, and pole traction behavioral performance.

REPORTABLE OUTCOMES

None for the past year. We anticipate two posters to be given at the Society for Neuroscience meeting in the fall of 2000, along with two research papers to be submitted for publication.

CONCLUSIONS

A number of major conclusions are derived from the first year of this project. First, the upregulation of dopamine transport occurring at low doses of PM (1.5 mg/kg) provides a ready mechanism for synergism with pyridinium toxins, such as MPP^+ . Investigating this synergism is a major goal of the second year of the project, after we perform additional studies to nail down the dose-response relationship for this effect.

Second, the loss of dopamine transport at higher doses of PM is probably related to other toxic effects, such as a reduction in mitochondrial activity. Even though the magnitude of the effect is small, any reduction in mitochondrial activity caused by PM and CPF may be significant over the long term. Although we have not yet performed GBR binding studies to estimate transporter density in striata from treated mice, our initial immunocytochemical studies suggests no deficit in DAT levels in mice treated with 200 mg/kg PM. We did not observe a loss of striatal dopamine after 100 mg/kg CPF or 200 mg/kg PM, which would have been expected if significant cytotoxicity had occurred. However, we hypothesized a "clumping" effect of dopamine could be occurring that serves to mask effects on dopamine when measured as total amount of transmitter by HPLC. We would like to try dopamine immunolabeling to see if this is indeed the case.

Third, the strong up-regulation of muscarinic receptors by PM was unexpected, and may play a role in reducing motor activity, since muscarinic agonists such as oxotremorine cause bradykinesia and tremor. This finding needs to be replicated, and lower doses run as well, to define the NOEL for this effect.

The good correlation between behavior and acetylcholinesterase inhibition for CPF is not too surprising, and these results confirm a number of previous studies done in rats and set the stage for more thorough studies of its effects in year two of this project.

These studies are significant as a body of research because they illuminate a number of significant actions in the neurotoxicology of insecticides, some of which are applicable beyond the scope of this research. The most significant finding is the upregulation of transport at low doses of PM. We have previously observed that the organochlorine heptachlor (Bloomquist *et al.*, 1998) and the pyrethroid deltamethrin increase dopamine transport (Kirby *et al.*, 1999). However, the latter studies did not include a dose-response analysis for this effect. Now, we have extended this observation to permethrin and shown that this action occurs at doses at least two orders of

magnitude below the LD_{50} . Thus, up-regulated DAT is a sensitive index of CNS exposure to insecticides and may be generalized to include other classes of neurotoxins as well. Studies on mitochondrial impairment have also provided additional significant findings, since mitochondrial dysfunction is implicated in a number of neurodegenerative diseases besides PD (Beal *et al.*, 1993). Thus, our observation of compromised mitochondrial function following insecticide exposure may broaden the possible roles of insecticide exposure in other neurological conditions.

REFERENCES

- Aston-Jones G, Shipley MT, and Grzanna R. The locus coeruleus, A5 and A7 noradrenergic cell groups. In: G. Paxinos, The Rat Nervous System (2nd ed.), pp. 183-213, Academic Press, San Diego (1995).
- Beal M, Hyman B, and Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? *Trends Neurosci.* 16: 125-131 (1993).
- Bloomquist J, Kirby M, Castagnoli K, and Miller G. Effects of Heptachlor Exposure on Neurochemical Biomarkers of Parkinsonism. In: "Progress in Neuropharmacology and Neurotoxicology of Pesticides and Drugs," (D. J. Beadle, Ed.) Society of Chemical Industry/Royal Society of Chemistry, Cambridge, United Kingdom, pp. 195-203, 1999.Bowman WC and Rand MJ. Textbook of Pharmacology, 2nd Ed. Blackwell, Oxford, (1980).
- Budavari S, O'Neil M, Smith A, Heckelman P, and Kinneary J. The Merck Index, 12th Edition. Merck & Co., Whitehouse Station, New Jersey, pp. 1741 (1996).
- Casida J, Gammon D, Glickman A, Lawrence LJ. Mechanisms of selective action of pyrethroid insecticides. Ann Rev. Pharmacol. Toxicol. 23: 413-438 (1983).
- Chaudhuri J, Chakraborti TK, Chanda S, and Pope CN. Differential modulation of organophosphate-sensitive muscarinic receptors in rat brain by parathion and chlorpyrifos. *J. Biochem. Toxicol.* 8: 207-216 (1993).
- Dawson R Jr, Beal MF, Bondy SC, Di Monte DA. Excitotoxins, aging, and environmental neurotoxins: implications for understanding human neurodegenerative diseases. *Toxicol. Appl. Pharmacol.* 134(1):1-17 (1995).
- Elliott M, Farnham A, Janes N, Needham P, and Pulman D. Insecticidally active conformations of pyrethroids. In: Mechanisms of Pesticide Action, Kohn GK, Ed. American Chemical Society, Washington, D.C. pp. 80-91 (1974).
- Ellman GL, Courtney KD, Andres V, and Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* 7: 88-95 (1961).
- Eriksson P and Fredriksson A. Neurotoxic effects of two different pyrethroids, bioallethrin and deltamethrin, on immature and adult mice: changes in behavioral and muscarinic receptor variables. *Toxicol. Appl. Pharmacol.* 108: 78-85 (1991).
- Filloux F and Townsend J. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. *Exp. Neurol.* 119: 79-88 (1993).
- Franklin, KBJ and Paxinos, G. The Mouse Brain in Stereotaxic Coordinates, Academic Press, San Diego pp. 258 (1997).
- Gomeza J, Šhannon H, Kostenis E, Felder C, Zhang L, Brodkin J, Grinberg A, Sheng H, and Wess
 J. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout
 mice. Proc. Natl. Acad. Sci. USA 96: 1692-1697 (1999).
- Goodwin BP, Anderson GF, and Barraco RA. Characterization of muscarinic receptors in the rat nucleus tractus solitarius. *Neurosci. Lett.* 191: 131-5 (1995).
- Haberland N and Hetey L. Studies in postmortem dopamine uptake. II. Alterations of the synaptosomal catecholamine uptake in postmortem brain regions in schizophrenia. J. Neural Transm. 68: 303-313 (1987).
- He F, Sun J, Wu Y, Wang S, and Liu L. Effects of pyrethroid insecticides on subjects engaged in packaging pyrethroids. Br. J. Ind. Med. 45: 548-551 (1988).
- Heikkila RE and Sonsalla PK. The MPTP-treated mouse as a model of parkinsonism: how good is it? *Neurochem. Int.* 20: 299S-303S (1992).

Hornykiewicz O, and Kish S. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 19-34 (1987).

Hudson PM, Chen PH, Tilson HA, and Hong JS. Effects of p,p'-DDT on the rat brain concentrations of biogenic amine and amino acid neurotransmitters and their association with p,p'-DDT-induced tremor and hyperthermia. J. Neurochem. 45(5):1349-55 (1985).

- Husain R, Gupta A, Khanna V, and Seth P. Neurotoxicological effects of a pyrethroid formulation, fenvalerate in rats. Res. Comm. Chem. Pathol. Pharmacol. 73: 111-114 (1991).
- Husain R, Malaviya M, Seth PK, and Husain R. Effects of deltamethrin on regional brain polyamines and behavior in young rats. *Pharmacol. & Toxicol.* 74: 211-215 (1994).
- Kirby ML, Castagnoli K, Bloomquist JR. In Vivo Effects of Deltamethrin on Dopamine Neurochemistry and the Role of Augmented Neurotransmitter Release. *Pestic. Biochem. Physiol.* 65: 160-168 (1999).
- Liu J, Chakraborti T, Pope C. Effects of chlorpyrifos on high affinity choline uptake in rat brain. Fund. Appl. Toxicol. The Toxicologist 15: 205 (1995).
- Liu J and Pope C. Comparative presynaptic neurochemical changes in rat striatum following exposure to chlorpyrifos or parathion. J. Toxicol. Environ. Health 53: 531-544 (1998).
- Marks M, Stitzel J, Romm E, Wehner J, and Collins MA. Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and α-bungarotoxin. *Mol. Pharmacol.* 30: 427-436 (1986)
- Miller GW, Kirby ML, Levey AI, and Bloomquist JR. Heptachlor Alters Expression and Function of Dopamine Transporters. *Neurotoxicology* 20: 631-638 (1999).
- Miller LG, Koff J, and Byrnes JJ. Chronic intermittent but not continuous cocaine administration produces sensitization and dopamine transporter upregulation. *Clin. Pharmacol. Ther.* 53: 199- (1993).
- Niemeyer G, Jurklies B, Kaelin-Lang A, and Bittiger H. Binding and electrophysiology of the muscarinic antagonist QNB in the mammalian retina. *Klin. Monatsbl. Augenheilkd.* 206: 380-3 (1995).
- Nostrandt AC, Padilla S, Moser VC. The relationship of oral chlorpyrifos effects on behavior, cholinesterase inhibition, and muscarinic receptor density in rat. *Pharmacol. Biochem. Behav.* 58(1): 15-23 (1997).
- Richfield E. Quantitative autoradiography of the dopamine uptake complex in rat brain using [³H]GBR 12935: Binding characteristics. *Brain Res.* 540: 1-13 (1991).
- Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, and Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54: 823-827 (1990).
- Slater T, Sawyer B, Strauli U. Studies on succinate-tetrazolium reductase systems III. Points of coupling of four different tetrazolium salts. *Biochim. Biophys. Acta* 77: 383-393 (1963).

APPENDICES

Resume: Daniel J. Karen 302 Cherokee Dr Blacksburg, VA 24060

EDUCATION

Clemson University, PhD, Environmental Toxicology University of Charleston, MS, Marine Biology Emory University, BS, Biology December, 1999 August, 1994 May, 1992

PROFESSIONAL EXPERIENCE

Research Assistantship, Department of Environmental Toxicology, Clemson University, SC. Organized and ran GLP research project for the South Carolina Department of Natural Resources (SCDNR). Assessed the effects of hardness on copper toxicity to fathead minnow fry.

Laboratory Manager, Department of Environmental Toxicology, Clemson University, SC Managed aquatic culture laboratory housing *H. azteca, F. heteroclitus U. imbecillis, D. magna, C. tentans, C. dubia, L. macrochirus, R. pipiens, A. vulgare, and P. promelas.* Managed use of aquatic exposure lab for dosing studies.

Research Assistantship, Department of Environmental Toxicology, Clemson University, SC Organized and ran GLP project for an industrial sponsor (Silver Council). Presented data at national and international meetings in Fall, 1997. Wrote and published report.

Membership Chair, Alpha Epsilon Lambda, Clemson University, SC

Organized and managed Spring, 1998 new member selection and induction into Clemson University's graduate and professional student honor society.

President, ENTOX Graduate Group, Clemson University, SC

Initiated and implemented members' ideas. Improved library and computing facilities, participated in community service, coordinated with faculty, and organized and ran group meetings with other officers.

Vice President, ENTOX Graduate Group, Clemson University, SC

Assisted the President. Initiated and implemented members' ideas. Improved library and computing facilities, participated in community service, coordinated with faculty, and organized and ran group meetings with other officers.

Teaching Assistantship, Department of Biological Sciences, Clemson University, SC Taught Biochemistry lab during the Fall, 1997 semester and Human Anatomy lab during the Spring, 1998 semester.

Teaching Assistantship, Department of Biological Sciences, Clemson University, SC Assisted and taught Human Anatomy lab during the Fall, 1995 and Spring, 1996 semesters.

SPECIAL TRAINING/CERTIFICATION

WET (Whole Effluent Toxicity) Testing, SETAC Short Course, 1999 Multivariate Statistical Analysis of Ecotoxicological Data, SETAC Short Course, 1998. Practical GIS for the non-GIS professional, SETAC Short Course, 1997 Environmental contaminant stress: Immune function in aquatic and terrestrial organisms,

Carolinas SETAC Short Course, 1997 Advanced Open Water SCUBA Diver, Professional Association of Diving Instructors (PADI), 1991

DISTINCTIONS/HONORS

- 1999 PRIMO 10 Student Travel Award
- 1999 Carolinas SETAC Best Student Platform Presentation
- 1998 Inducted to Sigma Xi
- 1998 National SETAC Best Student Poster Presentation Competition, 2nd Place
- 1997 Inducted to Alpha Epsilon Lambda
- 1997 National SETAC Student Travel Award
- 1995 Joanna Fellowship

PROFESSIONAL MEMBERSHIP

Society of Environmental Toxicology and Chemistry Society of Toxicology Alpha Epsilon Lambda Sigma Xi

PUBLICATIONS

Karen, DJ, and PE Ross. (2000). Xenobiotic impacts on the skeletal system: A review *Rev. Env. Contam. Toxicol. (In Prep).*

Karen, DJ, PE Ross and SJ Klaine. (2000). Sublethal impacts of pesticide exposure on *Fundulus heteroclitus*: Comparisons between lab-reared and wild-caught fish. *Env. Toxicol. Chem.* (*In Prep*).

Karen, DJ, PE Ross and SJ Klaine. (2000). A comparison of episodic chlorpyrifos and TCP exposure on *Fundulus heteroclitus. Env. Toxicol. Chem. (In Prep)*.

Karen, DJ, SJ Klaine, and PE Ross. (1999). Further considerations of the skeletal system as a biomarker of episodic chlorpyrifos exposure. *Aquatic Tox.* (*Submitted*).

Karen, DJ, DR Ownby, GP Cobb, SJ Klaine, and TW LaPoint. (1999). Influence of Water Quality Parameters on Silver Toxicity to Rainbow Trout (O. mykiss), Fathead Minnows (P. promelas), and the Waterflea (D. Magna). Env. Toxicol. Chem. 18(1):63-70. (Invited)

Karen, DJ, B Draughn, M Fulton, and PE Ross. (1998). Bone strength and acetylcholinesterase inhibition as endpoints in chlorpyrifos toxicity to *Fundulus heteroclitus*. *Pest. Biochem. Physiol*. 60:167-175.

Karen, DJ, BM Joab, JM Wallin, and KA Johnson. (1998). Partitioning of Chlorpyrifos between water and an aquatic macrophyte (*Elodea densa*). *Chemosphere*. 37(8):1579-1586.

Karen, DJ, DR Ownby, BS Day, RW Brown, DP Shupack, GP Cobb, and TW LaPoint. (1997). Influence of Varying Water Quality Parameters on Toxicity and Bioavailability of Ag⁺ to Rainbow Trout. In: The Fifth International Argentum Conference Proceedings: Transport, Fate, and Effects of Silver in the Environment. University of Wisconsin, Madison. USA.

Ownby, DR, **DJ Karen**, DP Shupack, BS Day, TW LaPoint, SJ Klaine, and GP Cobb. (1997). Using spectroscopy and voltammetry to evaluate silver activity in aquatic toxicity evaluations. In: The Fifth International Argentum Conference Proceedings: Transport, Fate, and Effects of Silver in the Environment. University of Wisconsin, Madison. USA.

Figures and Tables

.



Figure 1. Subchronic treatment procedure for determining parkinsonian effects of PM and CPF. Mice not receiving toxins are injected with vehicle (methoxytriglycol [MTG] for PM and corn oil for CPF).



Figure 2. Effect of CPF (100 mg/kg, sc) and PM (200 mg/kg, ip) on striatal dopamine levels. In this and all subsequent figures bars represent means \pm SEM. Results are compared to vehicle (corn oil for CPF and MTG for PM). No statistically significant effects were observed.



Figure 3. Effects of CPF (100 mg/kg, sc) and PM (200 mg/kg, ip) on striatal DOPAC levels. Results are compared to vehicle (corn oil for CPF and MTG for PM). Asterisk indicates statistical significance of CPF effect compared to vehicle (p < 0.03, unpaired T-test).



Figure 4. Representative dopamine uptake studies for mice treated with PM. The table beneath the figure summarizes the data and shows the calculated kinetic values, along with their standard statistical parameters. The mathematical equation used is standard for binding studies, so the program reports B_{max} and K_d values, which are identical to V_{max} and K_m values for these transport measurements.



Figure 5. Dose-response studies of dopamine uptake with PM, normalized to matched controls. Asterisks indicate statistical significance in a T-test (1.5 mg/kg compared to control, p < 0.08) or ANOVA (all other indicated doses compared to control, Dunnett's multiple comparison test, p < 0.01).





Figure 6. Molecular configuration of stereoisomers of permethrin. Structures are drawn after Elliott *et al.* (1974), along with their relative mammalian toxicities, as reported by Casida *et al.*, (1983).



Figure 7. Typical binding isotherm of [³H]GBR-12935. Symbols represent means with SEM bars. Binding parameters are also given (95% confidence limits).



Figure 8. Assay of mitochondrial integrity with thiazolyl blue (MTT) at various concentrations. Asterisk indicates a significant difference (p < 0.05) between control and 25 mg/kg CPF at 0.55 mM MTT.



Figure 9. Assay of mitochondrial integrity with thiazolyl blue (MTT) at three concentrations in mice treated with 50 or 100 mg/kg CPF. Asterisk indicates a significant difference (p < 0.05) between treatment and control ((ANOVA with Student-Newmann-Keuls post test, p < 0.05).



Figure 10. Reduction in MTT dehydrogenase activity in PM-treated mice. Asterisks indicate a mean level of activity significantly different from control (ANOVA with Student-Newmann-Keuls post test, p < 0.05).



Figure 11. Representative coronal brain atlas section, at 0.1 mm caudal to bregma, showing the caudate-putamen (Cpu) and the relative position of the four regions (filled circles) typically sampled from each section. Taken from Franklin and Paxinos (1997). LV = lateral ventricle; LGP = lateral globus pallidus.

FIGURE 12



23



Figure 13. Graphical analysis of effects of MPTP and PM treatment on DAT labeling.



DA Distribution After Treatment

Figure 14. Hypothetical distribution of dopamine (DA) in the caudate putamen (CPu) of control mice (top) and neurotoxin-treated mice (bottom). Light stippling in the top figure represents normal immunostaining of dopamine in the Cpu. Following toxicant treatment, large areas of the CPU are clear, indicating loss of dopamine, but others stain more intensely. Such an effect might occur as a homeostatic mechanism to restore overall dopamine levels in the CPu.

FIGURE 15



TH immunoreactivity in a striatal section (15 um) from a mouse treated with 100 mg/kg chlorpyrifos. A is a darkfield image and B is a higher magnification brightfield image of a portion of image A. Crosses represent identical locations on the two images. The white calibration bar in A is 100 um and the black bar in B is 25 um.



1.

Figure 16. Movement (left) and rearing (right) behaviors in mice treated with CPF. Asterisks indicate a mean level of activity significantly different from control (ANOVA with Student-Newmann-Keuls post test, p < 0.05).



Figure 17. Mice that fell from the pole following CPF treatment. Since this effect was calculated as a percentage from each group of treated mice, it will be need to be replicated. We prefer this approach as opposed to nonparametric statistical analysis.



Figure 18. Movement (left) and rearing (right) behaviors in mice treated with PM. Asterisk indicates a mean level of activity significantly different from control (ANOVA with Student-Newmann-Keuls post test, p < 0.05).



Figure 19. Mean descent time for mice treated with PM in the pole traction test. No statistically significant effects were observed in descent time, and none of the mice fell from the pole.



Figure 20. Acetylcholinesterase activity in the striatum following treatment with the indicated doses of CPF. The % inhibition at each dose is given inside the bars. Bars labeled by different letters are significantly different at the p < 0.05 level (ANOVA, Student-Newmann-Keuls post test).



Figure 21. Acetylcholinesterase activity in the striatum following treatment with the indicated doses of PM. Asterisks indicate a mean level of enzyme activity significantly different from control (ANOVA with Student-Newmann-Keuls post test, p < 0.05).



1) 1

4

Figure 22. Upregulation of striatal muscarinic receptors by treatment with PM. Significant effects were only observed on B_{max} , as judged by the nonoverlap in the 95% confidence limits.



Figure 23. Binding assay for [³H]nicotine in striatal membranes from mice, based on the procedures of Marks *et al.* (1986)..

Compound	Dose	Pellet
Corn oil	Control	P1
CPF	25	P1
CPF	50	P1
CPF	100	P1
Corn oil	Control	P2
CPF	25	P2
CPF	50	P2
CPF	100	P2
MTG	Control	P 1
PM	25	P1
PM	50	P1
PM	100	P1
PM	200	P 1
MTC	Control	P2
MIG	25	P2
	50	P2
	100	P2
PM DM	200	P2
PM	200	I 2

Table 1. Frozen, processed tissue samples from treated mice currently available for binding studies. P1 = first pellet composed of cell bodies and large cellular fragments. P2 = crude synaptosome fraction enriched in membranes from presynaptic nerve terminals.

r 1 - 5



Office of the University Veterinarian & Animal Resources

Dr. David M. Moore, University Veterinarian and Director CVM Phase II - Duckpond Dr., Blacksburg, VA 24061-0442 Office: 540/231-4991; FAX: 540/231-7367 Internet: moored@vt.edu

14 January 2000

MEMORANDUM

TO: Dr. Jeffrey R. Bloomquist Entomology

FROM: David M. Moore

SUBJECT: Environmental Extremes Experienced by Study Animals

This is intended to document the environmental extremes to which your study animals (in the study funded by the US Army) were exposed to over approximately 60 days at the end of 1999, and to explain the events which led to those conditions.

During March of 1999, both Dave Gemmell (Central Vivarium Manager/Supervisor) and I were contacted by the Virginia Tech Physical Plant Department and advised of the necessity to shut down the HVAC system in Litton-Reaves Hall which supplied a significant area of the building, including the Central Vivarium where your mice were housed. The shutdown was necessary to replace the primary exhaust fan unit which served the area. This would require the use of a massive crane to pluck the existing unit from the top of the 4 story component of the building, a crew of various trades to effect modifications to the mechanical systems to accept installation of the new unit, and use of the crane to hoist the new unit to the roof for installation. We were advised that this task would take approximately 3 weeks to complete. We were also advised that during that timeframe, the indoor air quality unit would be cleaning the interior of the ductwork and treating/coating the interior surfaces with an antimicrobial finish. Both Dave and I have experienced 3 previous major HVAC shutdowns, two which were planned, and one which was an emergency. We recognized, through our past experience, that the most ideal time of year to effect repairs was in late fall, as the cooler outside temperatures would facilitate maintenance of interior temperatures within the Vivarium. Thus we won a concession to delay the project until late October of 1999.

Dave and I discussed contingencies for the three-week outage. One option was to transfer all animals to other facilities on campus, but full occupancy at all facilities precluded that option. A second option was to completely depopulate the Vivarium, but a number of longterm ongoing studies could not afford the loss of valuable animals. A third option was to secure alternative facilities off-campus, but costs for rent, renovation, moving, and utilities would have exceeded three times the annual budget of the Central Vivarium for that 3 week period. The fourth option, which was selected, involved preplanning with Physical Plant to acquire and install mobile HEPA-filtered air conditioning units and temporary ductwork to temper the air and maintain cooling within the Vivarium during the 3 week period that the main HVAC was down.

Approximately two days before the system was set to be shut down, Dave Gemmel was informed that the process of cleaning the ductwork would take 6 weeks, not the 3 weeks as previously stipulated. Based on indoor air quality requirements stipulated by the Commonwealth of Virginia Department of Environmental Quality, we could not prevent the workers from performing the duct cleaning at that time. Visits to the other campus facilities confirmed that no space was available at that time for transfer of the animals. Two main HEPA-filtered air conditioning units were delivered and installed, along with ductwork, on October 17 and 18, 1999. Dave Gemmell coordinated schedules with the air quality crew to ensure that animal rooms were depopulated, by transferring animals to an open room, before entry of personnel for cleaning. All areas where cleaning took place were isolated with floor to ceiling plastic drapes.

On October 18, 1999 the HVAC system supplying the Central Vivarium was shut down. Overnight, there was a 7.2°F increase in the temperature in the room housing your mice. Unbeknownst to us, the mechanical room located below Rooms 7 & 8 was generating significant heat which directly impacted room temperatures within the Vivarium. In the 3 previous HVAC shutdowns mentioned earlier, none had involved shutdown of all primary and backup exhaust fans. The duct cleaning necessitated shutdown of all exhaust fans. Neither we nor Physical Plant had anticipated the significant impact of heat generation and transfer from the mechanical room on the Vivarium temperatures, as this was the first time in 18 years, since the building has been on line, that full shutdown of the HVAC system had occurred. Upon recognizing the increased temperatures, Dave Gemmell contacted Physical Plant to request the immediate installation of additional cooling units and fans. Two more units were delivered that same day, but required a water source for their operation. Special connectors had to be ordered, and were not received for approximately 5 days. A third unit was also delivered later that day, but it was determined that the breaker/circuit was not configured to accommodate the additional load. This required coring of the 1' concrete ceiling to run a line from another circuit. This took approximately 4 days to complete before the hookup was made.

Further compounding the situation was an unexpected heat wave at the end of October and into November, with outside temperatures approximately 30-40°F higher than would be typically expected. Our decision to initiate the project in late October was predicated on my 14 years in Blacksburg, and the relatively stable late Fall weather. Initially, Physical Plant configured the main HEPA-filtered air conditioning units to draw supply air from the hallway, but after Dave Gemmell and I pointed out that the system should be drawing outside air to ensure lower temperatures, they complied and installed additional ducting to the outside. However, higher than normal daytime <u>and</u> nighttime temperatures overrode any benefit of outside supply air, and temperatures again climbed.

By the 11th of November, the additional air conditioning units had been brought on line, and temperatures were moderated, but still not back to nominal levels. Around this time, a small number of the mice belonging to you and Dr. Klein were transferred to the CVM Phase IV facility. Space constraints precluded transfer of the remainder of your animals.

We were then told that duct cleaning was behind schedule, and might continue through the first week in December. Another warm front during the last week in November caused room/facility temperatures to climb again. After additional delays, the HVAC system was restored to full operation on December 27,1999.

I want to state, for the record, and for the benefit of your study sponsor, that you, as PI for your project, had not been adequately consulted prior to this shutdown related to the scope and magnitude of the potential environmental extremes, and this precluded you from exercising your scientific judgement to plan for this contingency. We recognize that had you, and we, known that the temperature extremes would have been that extensive, you could have delayed portions of your study to avoid the influence of environmental variables that were ultimately experienced. Our decisions and actions in this matter were predicated on our combined 38 years of lab animal facility operation and management, and our combined 24 years of operation of the Central Vivarium at Virginia

Tech. Our decisions were undermined, as previously stated, by unforeseen complications with generation of excessive heat in the basement mechanical room, with atypical/aberrant warm fronts during the late Fall months of 1999, and with abrogated agreements regarding adherence to schedules/timelines by the indoor air quality management and staff. It was fortunate that the temperature extremes (up to a high of 92°F) did not result in the death or illness of animals housed within the Central Vivarium during that 2 month period. And to date, no evidence of clinical illness has been found in any of the animal species housed within the Vivarium. But undoubtedly, the high temperatures had either a subtle or a profound effect on the data which you collected.

1 \$

Attached are the room logs for Room 7 for the months of October, November, and December 1999, which provide the daily high and low temperatures for the room. For comparative purposes, room logs for November and December 1998 for Room 8 (where your animals were housed at the time) have been provided. A comparison of those temperatures is provided in two graphs attached to this memo.

If you or your sponsor require any additional information/data regarding this matter, please let know, and I will be happy to assemble and provide the requested information.

Room #

DAILY ACTIVITY ROOM LOG Month <u>let</u> Year <u>1999</u>

____ Study ID _

Dare	Spec. Code*	т	emp	Check feed/ water per SOP 117 (v)	Check autowater per SOP 106 (v ²)	Checx time clock per SOP 105 (V)	- Initial/date	S = 5 M =	Ficci Swe Maj	rs deaned per SCP 119 ep (v) c (v)	Hearth Check (initia	s per SCP 106 Vdare)
		Hi	Lo					s	М	Initial/date	AM	PM
1	M	21	21	V		V	Pro Idilan			PKS 10/199	DKS IN/199	OKS 10/1/95
2	M	121	21		1-	1/	P510/2/99	И		P51012199	P310/2.199	PS 10/2/99
3	M	121	20		10	1	P51013199	4		4510/3/94	\$510/3/99	P510/3/99
4	M	21	70	1	$\mathbf{\nabla}$	•/	0010-4-99	V	7	NOU 10-49	PULO-99	10-199
5	m	21	20	\checkmark	\mathbf{N}	\mathbf{V}	195m-599	Λ	Λ	000 10398	0110-592	DU10529
6	m	21	70	1/		1	115699	e.	1	SNUS 6.99	BULLER.	001069
7	W.	2	20		1/	V	151017199	21.	-	1510/7/99	1510/7 99	PS1017/97
8	m	21	20	1	r	\checkmark	AC 10-8-94	1	1	AC 10-8-40	Q. 10-8-99	VB16.9.99
9	m	21	21	1/			P510/9/99	1		0510/9/99	0510/9/99	P310/9/99
10	M	21	21	V			P310/10 199	Χ	ĺ	P510/10/991.	1510/10/99	PS10/10/99
14	M	21	21	1/	\checkmark	\checkmark	PSic111 199 1	Z,		PSio 11 1991	PSic 111 1991	P510/11/99
12	m	22	20	V	V	\checkmark	TAN 10-1299		1	PSHILE	0710-129	69110128
13	m	22	70	V		V	NULD-1394	A.		116-1394	NOV 10-13-97	000101399
14	m	21	ZO	\checkmark		Í I	10-14-991	Ň	1	JID 14 TO	10-14-99	10-44
15	M.	22	171	\checkmark	1	\checkmark	Shuldrisgg	vc	1	nuloisa	101 10-15-1	Contons
16	M	21	79	\checkmark			PS10/099	1)x	1510/16/99	p310/16/99	PS 10/14/87
17	M	21	21	1/1	V	V	PSi0/17/99	<u>/</u>		3017 49	P.510/17/99	PS10/17/99
18	M	23	27	.V		~	MU10-1899h	Δ.	4	DU 10-0897	NAU 1018-29	mulost
19	M	27	26	V		\checkmark	QU16-1999	4	4	BUIDISA	010-1999	UN1997
20	m	28	27			\checkmark	DU10-76-			MJIDZ09	INID ZOAC	DO DOTOTE
21	M_	29	79		V	\checkmark	10-21-991	4		10-21-91	1010219	DN18-29
22	m	80	50			\checkmark	PPS5-010	Δu		AUN-STI		Na10-2297
23	M	30	30	\checkmark	~		150 23 99	4	1	510 23/99 1	510/23 99	40/23/92
24	M	30	30	V			R510/24 99	4	F	310/21/99/	510/24/99	500 pc/ 99
25	m	31	29	V	V		10/102599	4	1	QU10-259	100 10-21 91	01025-11
26	M	31	30				DW 107699	41	Þ	mulo764	MN10-7699	10764
27		31	28	V		<u> </u>	DW 10-2799	<u>A</u> u	4	Julo 2795	MUISTIG	901D-2197
28	M.	29	<u>78</u>	V	1	4	W16-28-94	1	1	MD-CETE	000 10-254A	CHU LOZSER
29	M_	31	<u>31</u>	V	•		PUID-29-99	4	P	112-25-51	110-2999	11-12-011
30	M	31	31	~	1 h	,	P510/30/95 1	4	12	Sic 30 99 F	310 30 99	1510/30/49
31	M	37	21				1410 181 199 1.	1	1.	0410 219A J	Km 81 49	Acia 181 49

*Species Code:

M=mouse R=rat RB=rabbit

Shut

GP=guinea pig C=cat CK=chicken

G=gerbil H=hamster Q=quail

GR=grouse S=sheep Other:

____Room # ____

7

Month Nov Year 1999

_____ Study IC _

						-		_	·			•	1			
				Check	Gieck	time				Ficer	s daaned	i per			me har S	79 *rs
Data	Scer	Т	ma	fæd/ water per	per SOP	per	- Initia	Vilare			3CF 119			in:		
	Code*			SCP 117	105 (√)	SCP 105			S: M	= Swei = Maș	ep (v) : (v)					
				(*)		(٧)								•		
		Hi	Lo				[s	М	Initial	date		AM	·	PM
1	M	23	32	V			NUI	-1-11	2		New 1	1-1-91	N.)1-1-7	7DW	<u>11-1-19</u>
2	m	33	32		1	17	01011-	2-99	M	\checkmark		299	Ow	1-29	ille	11-2-95
3	m	28	78	V	$\overline{\mathbf{V}}$	V	12/1-	399		1	Revil-	399		1-399	i QV	11-3.99
4	in'	28	710	1			DW 11	4-99		1	11	44	M	1149	ion	1-49
5	m	78	78	~			100 11-	599	V	1	MU II.	549	(m)	11-5-9	1	11-599
6	m	29	28	V	1/	1	0511/4	, 199	1	- 1	5 ji 1	199	F31	10/94	175	11/10/99
7	m	311	28	~	/		P5117	199			PS111	199	45111-	1199	PSI	1/7/99
8	m	30	77	~		\checkmark	DAN 11	-8-99		Λ	Du [1-	8-971	DUI	-899	100	111-849
9	m	78	27	\checkmark	1		GUU-	9.99	i		mili	999	MU I	1-999	m	11997
10	In	21	76	V	~	~	Eu11-	1099			10 11-	1091	Devil	-10-97		1-1097
11,	IM	76	95	V	~		Own-	11-99	1		BUIL	1199	Dow	11-11-9	4 km	<u>111-11-99</u>
12	M	75	75	~	~	~	DAN 11-	1299		M	mil.	1299	De	1HZ9	4 Car	11-129
13	M	251	25		$\overline{}$	レ	151113	99	レ	-	Kuli3	99	psul	13 79	PSII	13 29
14	m	25	24	レ	~		PSILIU	199			<u>1311/14</u>	79	P51	1/1/199	PSII	11/22
15	m	25	23	~	\checkmark		BUILIS	599		Δ	NI	599		11-155	F (D)	IHS 9
16	m	75	23			\checkmark	MUH	49	1	Ň	MIH	699	m /	1460	OR	1167
17	m	24	72	~	\checkmark	$\mathcal{J}($	Thui-	11-91	\checkmark	Λ	11-	<u>.17-99</u>	QAI	1179	XXX	W11+79
18	M	24	23	V			MJI-1	1849		A	NUR-	1841	G NI	HSY		-1899
19	m	74	23		\checkmark	\checkmark	MUL-	1999	1	$\sqrt{1}$	mil-	1994	In	11-199	9 mi	11-1997
20	M	25	23	~	~	V	SC Illa	201991	1		ic 11/2	0 99	Se ni	20199	SE II	20/99
21	m	26	26		/	~	P5 11/2	199	ノ	IF	⁹ 511/21	99 1	<u>Sul:</u>	21 99	PSIL	21179
22	m	78	76	1/1		\checkmark	STN 11-2	Z99	V	1	au li-	729	Paul	1-229	î Ferj	1-22-11
23	m	74	78	1	1	$\overline{\mathbf{V}}$	Pall-	7399	X	N	ñ NI	237	ON !!	11.73	to Car	1112397
24	m	30	25			~		2499	V	A	Bull	7499	BUI	1-249	\$ DAU	1249
25	m	28	28	V			PANIL!	759	V	PT	1011-2	S'Ŷk	MUI	2599		-2599
26	6	20	28	V	V	V	SC 11-	16-99	~	~	se uls	Lin	y nl	26/45	15 ml	26/19
27	m	X	26		V	V	Se 11/2	7/99	V	2		719919	8 11	27/99	8/11	17/95
28	m	18	361	VI	~	VI	50 11/2	8199	V	Ş	e via	1/55 19	x Illa	8/55	18111	18/97
29	m	28	26	V	V	\checkmark	81120	<u>î</u> 99	M	1	sells	<i>hink</i>	i nla	x/m	182 h	03/37
30	mi	251	241			Vk	DAN 11-	30 99	\checkmark	ND	N11-3	6994	MUI-	3039	BULI	-3097
31		1					· <u>J</u>			ľ	; 		U			l

*Species Code: M=mouse R=rat

R6=rabbit

GP=guinea pig C=cat CK=chicken G=gerbil H=hamster Q=quail GR=grouse S=sheep Other:

						LAB	ORATO	DRY AN	IMAL	RESO	URCES	-	
e eş	بر						DAILY	ACTIVI	TY ROO	OM LO	DG		
_	_		1		• • • •	Der.		IG	91				
	Room	#	<u> </u>		Month	<u>UU</u>	Y	ear <u>19</u>	1		Study ID		
						<u> </u>							
					Check	Check	Checx time	;		Fic	cors cleaned per		
	Data	Spec.	Т	çmə	feed/ water per	autowater per SOF	dock per	- Initial	<i>i</i> data		50P119	Health Che (inn	cks per SCP 106 cal/date)
		Coce			SOP 117	105 (√)	SCP 105			5 = 5v M = M	м со р (v) м со р (v)		
					<u> (v)</u>		(Y)	1					
			H	La						SM	Initial/cate	AM	PM
	1	m	128	25			11	KONU12-	197	4-	10012-1-4	UQUIC-19	7 001217
	. 2	m	127	26	- 1/			100VIZ	241	170	1000122	10012-29	40W 1ZZ
	3	M	27	20	V/			MAN 17	ረግ	VV	10012-39	109N1229	714112-34
	4	<u>M</u>	\underline{a}	126	<u> </u>			SC 121	<u>y</u> ra		8.12/4/9	SC. 12/4/99	5/2/2/4/75
	5	M	27	176	\sim		V	8 B	255		Facia BAG	<u>Sc 12/55</u>	8 125/55
	6	Ŵ	74	27	V /		V	MAN 12	699	VV	MIZE 91	MU1269	001126
	7	M	29	Z1	V	V	V	MUSIZ-	<u>'-1</u>	VV	M&12-7-17	1112-1-7	1 MU812-7-4
ļ	8	W	24	24		V	Ý	se 218	199	$\frac{\sqrt{2}}{2}$	1861218199	Se 12/18/99	86 12 8/25
ļ	9	M	25	23	V	V	Ŷ	N/012-9	1-11	VV	Mp12-9-T	MUS12-9-T	IMKB12-9-1
ļ	10	M	25	23	V	V	V	DILZ-1	099	\overline{V}	10112-104	F 1012-109	01012-109
.	17	M	20	<u>an</u>	J			<u>Se 12-</u>	11-99		Se BIILKG	2/2/11/95	8212/1197
	12		211	de			<u> </u>	Seral	12/99-1	4	z ial pige	Sebjegg	ECIDIDEF.
Ļ	13		<u>971</u>	31	V		V ¢	<u> 12 12 17</u>	2991	VV	Re12/13/99	se alizes	8-13/13/55
Ļ	14	<u>m</u>	48	ZX	V	V		JAN 12-	44	V v	Mar 12/4	TTOME/14	FEDOWIZ-H-
Ļ	15	W/	15	73				M12-	1599	VV	01121599	100121599	10012-151
Ļ	16	M	20	3	V	\checkmark	VA	OUIZ-	1644	VV	DPU 12-16 99	000 12-169	19901Z-169
ļ	17		26	(3)				MB12-1	7-91	Nν	NYS 12-17-17	MUB12-17-97	MS-17-17
Ļ	18	IX I	5	24			<u> </u>	<u>sarail</u>	192 1	11	20 13 18 69	52 01899	50118/32
F	19	\mathbb{N}	251	251	<u>~</u>	~		6.0/10	1 <u>2</u> 01		2 Diales	5- 12/19/CC	Control Co
	20	M	$\frac{C}{2}$	74	· V	<u> </u>		MV12-0	044	AV	MU12-20-99	10012-2019	100 12 209
-	21	mk	51	4	$\frac{v}{ }$	V		NIET	-441	1.	MN12-2199	DW 2-214	101/2-21-92
Ļ	22	\mathbb{D}	<u>do</u> [22	<u></u>			AV12-2	2711		WIC-22-14	10hu 12-2299	00W122291
-	23	M	(1)			V	V	<u>avic-c</u>	5771	///	01117-634	101122391	(J) Z-737
	24	in r	15	2				0112-6	<u>4 %.</u>	11	UNIZ-44	10 17-744	CAN12244
Ļ	25	$\frac{N}{12}$		$\frac{22}{21}$	~_			<u> 26129 X</u>	199 1		X17X64	31. 12 CUS	CY 12/2/94
Ļ	25		20 1	24			V	<u>scialal</u>	IGG Y		5012/2999	x12/26/55	Se12/26/45
Ļ	21	<u>/Y_k</u>	510	3		_ <u>/ '</u>	V Q	MULCC	(77/L		Day 12-27-55	DW12-274	M112-279
F	28	MA L	41	$\underline{(0)}$	V	\mathcal{I}		MIZ-C	28 441	/1/	MU12-2874	USIU 12 28-19	UPN12287
-	29	N	$\frac{2}{2}$	$\underline{\mathcal{O}}$	V	<u> </u>		MIGO	799		112-214	100116-6799	KON 12-277,
-	30	M		$\frac{1}{2}$	XX			M/12:3	o Mi		MMC204	01/2-3071	UN16304
L	<u>ا</u> اد	111 2	4	C[]	~	V		NO16-3	01-1711	<u> </u>	N-212-31-17	MAS 12-31-17	<u>MG 12-31-77</u>
								V			-	V	V

*Species Code: M=mouse R=rat RB=rabbit

•

-

GP=guinea pig C=cat CK=chicken G=gerbil H=hamster Q=quail GR=grouse S=sheep Other:

....

						DAILY	ACT	τινιτγ	ROC	ЭМ	LO	G		
Roon	n #	g		Month	Nov		Year	19	58			Study ID		
									/		_ `			
						Check				- -				P
				Check	Check		Ì				Floo	ors cleaned per		
Date	Spec	. 7	Temp	water pe	per SOP			Initial/da	te		. 6		Health Ch	ecks per SOP 106 iitial/date)
				117	100(1)	106				M	= 5we = Mo	ρ (v)		
		I Hi	lio			(*)					1		<u> </u>	
1	1 1 1	-	122							.7	141		AM	PM
2		10	200	+			8	511-1-9	8	ľ		0011-1-98,	011-1-92	2 (141-1-98)
3	14	00	100					5)1-2-	78	V	۷.	1011-2-98	13-11-2-11	
4	M	77	12		<u> </u>		GA.	<u>) -3-</u>	2	K-A	V/	Apr 3-9		3
5		21	23					<u>-11-4</u>	•11		7	N. 8/1-4-78	114-11-4-17	1311.4.98
6		24	0			+-/	<u>P</u> <u>2</u>	11-5	-T8		Y	115//-5-97	IK 11-5-7	PM 11-5-98
7			00				80	11-6-	72	•		101-6-97	<u>en ll'6-9</u>	Sallar Co-98
8		02	22			+		<u>11-7-</u>		ø		BI-7-48	201-7-1	1881-7-D
9	100	122	27				021			쉬		511-8-70	88118-10	85118-70
10		22	20					1-4-		4		0911-448	0m/1-49	5 POSULI-148
114	M	01	20				5	11-10-	70		TK	311-10-88	2311-10-12	5 4 4 10 - <u>48</u>
12	M	al	12				20		10		-	AR 11-11-18	ASIF11-48	1511-11-18
13	N	20	20			V.	125	<u> - }</u>	3	¥	¥ļ.	12511-295	24 11-12-4	12511-2-92
14	M	0	22	~	./		Z	<u>1-12-</u>		╈		2/5/1754	<u> 1311-13-7</u>	1-1-15-18-
15	M	25	3					-14-	X	X		1311-H-2	191-14-	
16	m	22	77				701	- <u></u>	B				611-15-1	8911-15-0
17	M	22	22		/	/	212	<u>((* 19</u> ()	20	Ŧ	X			EW11-16-75
18	M	20	02		~	7			10	7			231-17-4	2-1-17-92
19	M	22	22	->-			ALIL	19.0		+		311-18-18	2311-18-12	<u>-811-18-98</u>
20	M	22	22	•		-/	d.a.	20					101-14-18 1411 - 20	BCI-H-B
21	M	22	22	- V		- /	1.2.1	20-4	x [Ŧ		101-20-74	311-20-7P	1-20-10
22	M	22	20	~			at la la	21-42		7		011-21-98	131-21-98	8411-21-98
23	M	22	21	1		V I	424	inz.C	0		Æ	211-12-70	-1311-22-18	151-2-10
24	M	22	21	1		/	AVA I				79		AL 11 24 00	AUDI 13-15
25	N	20	21	~	~	1 - 1		.10					131124-1X	50124-78
26	M	20	21			7 8	Vall	21 9	6	≁			134247-48	
27	M	24	21				Enal.	-71		7.		IL 1 The set	1-26-78	11011-06-98
28	M	24	21	\checkmark				30.1	20	⊁	15	Malling Co		Condrito
29	M	24 :	1	<u>_</u>		71	Mi li-	29.0	BI.	X		A H- TO AG		
30	M	24	24	$\overline{\mathbf{v}}$		7		-		1	Ê	31-22-29		
31			₽ = _			<u> </u>	P			+		H-278	ALCONG	3511-20-70
المستحد		l_					¥				-47	<u> </u>		

LABORATORY ANIMAL RESOURCES

*Species Code: M=mouse R=rat RB=rabbit

-

13 3

GP=guinea pig C=cat CK=chicken G=gerbil H=hamster Q=quail GR=grouse S=sheep Other:

		-				DAILY	ACTIVITY RO	ом	ĹO	G		
loom	#	8		Month	Dec.	Y	ear 1998			Study ID		
Date	Spec. Code*	Т	emp	Check feed/ water per SOP 117 (v)	Check autowater per SOP 106 (√)	Checx time clock per SOP 106 (v)	Initial/date	S M	Flo = Sw = M	ors cleaned per SOP 119 veep (v) op (v)	Health Checi (Initia	ks per SOP 106 al/date)
		Ні	Lo					s	м	Initial/date	AM	PM
1	M.	24	21			1	1612-1-98	V	V	10612-1-98	12-1-98	12-1-9
2	M	24	21		100		6.12-2-58	1.	1	12.258	\$212-2-58	92/2-2 - 9
3	M	24	22		~	~	165 12-3-48	V	1	KES 12-398	KSC 19-2-98	112512-3.9
4	X	24	23				500 12-Al-98	~	V		maia-4-98	1012-4-9
5	M	Af	23				8325-98	~		125-1	1012-590	24259
6	K	124	23	V			4926-98	~		0012698	\$12-6-9	\$2-6-9
7	M	24	23		- /	/	EB12-7-98	\mathbb{N}	$\sqrt{2}$	1312-7-98	0312-7-98	# KB-7-
8	M	26	23			1	0612-8-98	~	1	3812-84	6812-8-4	ARA-
9	M	24	23				13129-98	\square	\checkmark	53299	10B-998	112999
10	<u>N</u>	34	22				EZ 612-10-98	\bigvee	\checkmark	62612-10-78	Q.BQ.10-78	X142-10-98
11	NL	24	23			\checkmark	Fitis13-11-98	\mathbb{N}	$\sqrt{2}$	1317-11-99:18	1312-11-19:	83171198
12	M	$\langle \chi \rangle_{i}$	33	V	~	ist .	LES 12 RAP	U´)	X85/2724	1551272-1-	1255 12-12-14
3	M	24	23	V	V.	V	125 iali3/18	2	<u> </u>	KESALEME	KES A/13/12	KES 12/BAG
4	<u> </u>	23	2.2				AB12-14-98	\square	\checkmark	AB12-14 95	RA-H-F.	F3 67-14-98
5	<u>MC</u>	23	12.2	\checkmark		\checkmark	AR12-15-98		V :	1317-154.	13-15-99.	231.7-15-96
5	<u>[v]</u>	20	22		1	<u> </u>	B12-16-96	1	V' 5	1-12-16-75	3-12-110-514;	17-16-94
	11	24	37	V	1 -	<u> </u>	1312-17-18	V	V	1:513-17-16/	1313-17-16	4217-8
8	M	23	33		V	<u> </u>	6312-15-98	~	~	AB12-18-78	B12-18-78	BB-18-9
3	M	23	<u>x3</u>	V	V	<u> </u>	KES 12-19-98	4		JKES 12-19-75	XES 12-19-45	XES 12-1898
	\mathcal{M}	23	22				Kis 12-20-98			KES12-20-58	155 Dr-20-TF	Kis 12-20-98
	<u> </u>	23 6	2.2				KIS 2-21-58	<u> </u>	4	KES Walts K	ES 12-21-98	KES 12-21-98
3		25	22	V	<u></u>		KES 12-77-98	~	4	KES 12-22.98 k	15 12-22-98	DIN 1222
4		10	22			-	4012-2378	$ \rightarrow $		<u>20 12-23-5802</u>	2/2-23-58	Sp 12-23-58
5	Mi I	1) 72	77	×	-		K451224-58	<u>×</u>	K	5 12-2494 1	KES Q-2498	Kr512-2498
6	~	22	$\frac{2}{2}$	·	· ·	γ 	11.0.2-20-18	<u>'</u>		4.11.12.15-14 100 - 20-14	<u>HX17-15-95</u>	1.312.25-78
7	M	22	22	<u> </u>			K23 12-20-78		-	K(S 122298 L	3 2 de 417 .	4512 74 181
8	M	20					155 12 a 1-74	4		KS Kally	25 12-2748 K	<u>25 12 77-75</u>
9	M	12 12	<u>20 </u> 12	K			KLS 12 00 48		\exists	K25 K-28 48 K	25 12-28-44	KSS12-28-7F
0 1	M	22	22 22			<u></u>	NCS K-21-18	r 1	+	<u>NZS 12-78-12-12 /4</u> Car 12-21	2512-29-98	NUS /2 27-78
1	M	22	$\frac{2}{3}$				1217-30-78 1211 2-21-65		ť	12122-12 12 14 12	12 30-58	64712-30-58 64112-30-58
	<u> </u>	AP			<u>v 1</u>	<u> </u>	$\left(\frac{1}{10} \times 10^{-1} \right)$	<u> </u>	4	()	<u>"12 17. 1</u>	<u>76, 12-21-16</u>

LABORATORY ANIMAL RESOURCES

*Species Code: M=mouse R=rat

RB=rabbit

.

-

•

٠

GP=guinea pig C=cat CK=chicken G=gerbil H=hamster Q=quail GR=grouse S=sheep. Other: وتقرير والمحافظ

Hi Temps	Rm 7 Oct 99	u=24.9	2 773	32	- C	2	2.9	3		31	30	06	30	29	u=∠1.28	2 383 27	23 23	21 21	21 21	22 u=30 22	21 2 390 21	22 32 22	22 31 22	21 31 21	21 29 21	21 31 21	21 31 21	21 31 21	21 30 21	21 30 21	21 30 21	21 29 21	21 28 21	21 27 21)	fi s t	ric shu (f) sh Gul	er ter ut	to loc do	on wr nt
-	п														u=20.44	N 368	22	21	20	20	20	20	20	21	21	21	20	20	20	20	20	20	21	21		ŗ	ri L	or td	t	b Ma
o Temps	Im 7 Oct 99	u=	M																	u=29.23	X 380	31	31	31	28	28	30	29	30	30	30	29	27	26		ی بر ح	ft	er itd	!œ	un.
		-24.12	748	31	3	31	28	28	30	29	30	30	30	29	27	26	22	21	20	20	20	20	20	21	21	21	20	20	20	20	20	20	21	21		f	ίı	(n	201	iħ
HI Temps	Rm 7 Nov 99		u=27.33	№ 820	N	28	28	28	28	28	30	20	28	26	25	24	24	24	25	25	25	25	25	26	27	28	30	30	29	28	28	28	33	33						
Lo Temps	Rm 7 Nov 99		u=26.13	2 784	24	26	26	26	28	28	28	28	26	26	23	23	23	22	23	23	24	25	25	25	26	27	27	28	28	28	26	28	32	32						
Hi Temps	Rm 7 Dec 99	u=25.65	N 795	22	22	22	24	25	25	24	25	26	26	25	27	25	25	26	26	25	28	27	27	25	25	25	24	29	29	27	27	27	27	28						
Lo Temps	Rm 7 Dec 99	u=24.03	N 745	21	20	20	20	23	24	23	23	23	23	24	24	25	24	23	23	23	28	27	26	24	23	23	24	27	27	27	26	26	26	25						
Hi Temps	Rm 8 Nov 98		u=23.03	69 M	N	2	Ņ	Ņ	N	Ņ	2	2	2	2	2	22	N	2	2	2	N	2	Ņ	Ņ	N	22	N	N	N	N	2	N	2	2						
Lo Temps	Rm 8 Nov 98		u=21.87	1 . <u>N</u> 656	4 24	4 21	4 21	4 21	4 21	4 21	3 21	3 21	3 22	2 22	3 22	22	22	3 22	3 22	22	2 22	2 22	22	1 22	3 22	2 22	3 22	3 22	22	23	2 22	2 22	2 22	3 22						
Hi Temps	Rm 8 Dec 98	u=23.45	E 727	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	23	24	23	24	24	24	26	24	24	24	24	24	. 24	24						
Lo Temps	Rm 8 Dec 98	u=22.32	N 692	23	23	23	22	22	22	22	22	22	22	23	22	22	22	22	22	22	22	23	22	23	22	23	23	23	23	23	23	22	21	21						

ANIMAL ROOM TEMPERATURES (°C) FOR ROOMS 7 & 8 IN THE CENTRAL VIVARIUM Litton-Reaves Hall Virginia Tech Blacksburg, VA



Series 2, bottom line = Nov. 1998 u=23.03 (73.45°F) Series 1, top line = Nov. 1999 u=27.33 (81.19°F)





Series 2, bottom line = Dec. 1998 u=23.45 (74.21°F) Series 1, top line = Dec. 1999 u=25.65 (78.11°F)